AzTrials
AzTrials

OsteoporosisPhase 3NCT00205777

Study Evaluating Bazedoxifene Acetate In Osteoporosis In Postmenopausal Women

A Phase 3 study testing Bazedoxifene Acetate in people with Osteoporosis, run by Pfizer at 375 sites in 30 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of this study is to determine whether bazedoxifene acetate is safe and effective in the treatment of osteoporosis in postmenopausal women. Read more about this study

Who is it for?
Ages 55 to 80 years, women only
Conditions the study is for
Osteoporosis
What is being tested?
Bazedoxifene Acetate
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
7,609 participants
Where
375 sitesin 30 countries
Study dates
Dec 2001to Sep 2010
Phase
Phase 3
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 55 to 80 years
  • Women only
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Must be at least 2 years postmenopausal
  • Osteoporotic subjects without vertebral fracture who meet BMD criteria, or Osteoporotic subjects with vertebral fracture

Who cannot join

  • Diseases that may affect bone metabolism
  • Vasomotor symptoms requiring treatment
  • Known history or suspected cancer of the breast
  • Active or past history of venous thromboembolic events

Trial locations and contacts

375 sites in 30 countries.

375 sites in 30 countries

United States205 sites
  • Pfizer Investigational Site

    Aberdeen, South Dakota, 57401

  • Pfizer Investigational Site

    Akron, Ohio, 44312-1647

  • Pfizer Investigational Site

    Akron, Ohio, 44313

  • Pfizer Investigational Site

    Albuquerque, New Mexico, 87102

  • Pfizer Investigational Site

    Albuquerque, New Mexico, 87106

  • Pfizer Investigational Site

    Albuquerque, New Mexico, 87109

  • Pfizer Investigational Site

    Altoona, Pennsylvania, 16602

  • Pfizer Investigational Site

    Anaheim, California, 92801

  • Pfizer Investigational Site

    Anderson, South Carolina, 29621

  • Pfizer Investigational Site

    Augusta, Georgia, 30909

  • Pfizer Investigational Site

    Aventura, Florida, 33180

  • Pfizer Investigational Site

    Avon, Indiana, 46123

  • Pfizer Investigational Site

    Bangor, Maine, 04401

  • Pfizer Investigational Site

    Bangor, Maine, 4401

  • Pfizer Investigational Site

    Bellaire, Texas, 77401

  • Pfizer Investigational Site

    Belton, South Carolina, 29627

  • Pfizer Investigational Site

    Berkeley, California, 94705

  • Pfizer Investigational Site

    Bethesda, Maryland, 20817

  • Pfizer Investigational Site

    Beverly Hills, California, 90211

  • Pfizer Investigational Site

    Billings, Montana, 59101

  • Pfizer Investigational Site

    Birmingham, Alabama, 35233

  • Pfizer Investigational Site

    Birmingham, Alabama, 35249-7201

  • Pfizer Investigational Site

    Birmingham, Alabama, 35294-3708

  • Pfizer Investigational Site

    Bismarck, North Dakota, 58501

  • Pfizer Investigational Site

    Bismarck, North Dakota, 58503

  • Pfizer Investigational Site

    Boca Raton, Florida, 33432

  • Pfizer Investigational Site

    Boise, Idaho, 83702

  • Pfizer Investigational Site

    Boise, Idaho, 83704

  • Pfizer Investigational Site

    Boise, Idaho, 83712

  • Pfizer Investigational Site

    Boston, Massachusetts, 02115

  • Pfizer Investigational Site

    Bozeman, Montana, 59715

  • Pfizer Investigational Site

    Bridgeport, Connecticut, 06606

  • Pfizer Investigational Site

    Brookline, Massachusetts, 02445

  • Pfizer Investigational Site

    Brooklyn Center, Minnesota, 55430

  • Pfizer Investigational Site

    Cadwell, Idaho, 83605

  • Pfizer Investigational Site

    Camp Hill, Pennsylvania, 17011

  • Pfizer Investigational Site

    Cape Coral, Florida, 33990

  • Pfizer Investigational Site

    Centerville, Ohio, 45459

  • Pfizer Investigational Site

    Champaign, Illinois, 61820

  • Pfizer Investigational Site

    Charlotte, North Carolina, 28207

  • Pfizer Investigational Site

    Charlotte, North Carolina, 28209

  • Pfizer Investigational Site

    Charlotte, North Carolina, 28277

  • Pfizer Investigational Site

    Cheyenne, Wyoming, 82001

  • Pfizer Investigational Site

    Chicago, Illinois, 60612

  • Pfizer Investigational Site

    Cincinnati, Ohio, 45236

  • Pfizer Investigational Site

    Cincinnati, Ohio, 45249

  • Pfizer Investigational Site

    Clearwater, Florida, 33761

  • Pfizer Investigational Site

    Cleveland, Ohio, 44122

  • Pfizer Investigational Site

    Dallas, Texas, 75230-2513

  • Pfizer Investigational Site

    Dallas, Texas, 75230

  • Pfizer Investigational Site

    Dallas, Texas, 75231

  • Pfizer Investigational Site

    Dallas, Texas, 75243

  • Pfizer Investigational Site

    Daytona Beach, Florida, 32114

  • Pfizer Investigational Site

    Daytona Beach, Florida, 32117

  • Pfizer Investigational Site

    Decatur, Georgia, 30033

  • Pfizer Investigational Site

    Delray Beach, Florida, 33484

  • Pfizer Investigational Site

    Duncansville, Pennsylvania, 16635

  • Pfizer Investigational Site

    Evansville, Indiana, 47712

  • Pfizer Investigational Site

    Evansville, Indiana, 47714

  • Pfizer Investigational Site

    Evansville, Indiana, 47750

  • Pfizer Investigational Site

    Fall River, Massachusetts, 02720

  • Pfizer Investigational Site

    Fall River, Massachusetts, 02721

  • Pfizer Investigational Site

    Fargo, North Dakota, 58103

  • Pfizer Investigational Site

    Fargo, North Dakota, 58104

  • Pfizer Investigational Site

    Flowood, Mississippi, 39232

  • Pfizer Investigational Site

    Fort Myers, Florida, 33916

  • Pfizer Investigational Site

    Fort Myers, Florida, 33919

  • Pfizer Investigational Site

    Fresno, California, 93710

  • Pfizer Investigational Site

    Fresno, California, 93720

  • Pfizer Investigational Site

    Gainesville, Florida, 32601

  • Pfizer Investigational Site

    Glendale, Arizona, 85306

  • Pfizer Investigational Site

    Grand Rapids, Michigan, 49503

  • Pfizer Investigational Site

    Grand Rapids, Michigan, 49546

  • Pfizer Investigational Site

    Hamden, Connecticut, 06518

  • Pfizer Investigational Site

    Henderson, Nevada, 89014

  • Pfizer Investigational Site

    Holiday, Florida, 34690

  • Pfizer Investigational Site

    Houston, Texas, 77030

  • Pfizer Investigational Site

    Huntsville, Alabama, 35801

  • Pfizer Investigational Site

    Idaho Falls, Idaho, 83404

  • Pfizer Investigational Site

    Jackson, Mississippi, 39216

  • Pfizer Investigational Site

    Jamestown, North Dakota, 58401

  • Pfizer Investigational Site

    Jefferson City, Missouri, 65109

  • Pfizer Investigational Site

    Johnstown, Pennsylvania, 15904

  • Pfizer Investigational Site

    Kalamazaoo, Michigan, 49048

  • Pfizer Investigational Site

    Kalamazoo, Michigan, 49048

  • Pfizer Investigational Site

    Kansas City, Kansas, 66160-7136

  • Pfizer Investigational Site

    Kettering, Ohio, 45459

  • Pfizer Investigational Site

    La Jolla, California, 92037

  • Pfizer Investigational Site

    Lake Worth, Florida, 33461

  • Pfizer Investigational Site

    Lakewood, Colorado, 80227

  • Pfizer Investigational Site

    Langhome, Pennsylvania, 19047

  • Pfizer Investigational Site

    Largo, Florida, 33773

  • Pfizer Investigational Site

    Lemoyne, Pennsylvania, 17043

  • Pfizer Investigational Site

    Libertyville, Illinois, 60048

  • Pfizer Investigational Site

    Lincoln, Nebraska, 68510

  • Pfizer Investigational Site

    Longmont, Colorado, 80501

  • Pfizer Investigational Site

    Louisville, Kentucky, 40207

  • Pfizer Investigational Site

    Louisville, Kentucky, 40291

  • Pfizer Investigational Site

    Lousiville, Kentucky, 40291

  • Pfizer Investigational Site

    Lyndhurst, Ohio, 44124

  • Pfizer Investigational Site

    Madison, Connecticut, 06443

  • Pfizer Investigational Site

    Manchester Twp, New Jersey, 08759

  • Pfizer Investigational Site

    Mayfield Village, Ohio, 44143

  • Pfizer Investigational Site

    Memphis, Tennessee, 38104

  • Pfizer Investigational Site

    Memphis, Tennessee, 38119

  • Pfizer Investigational Site

    Memphis, Tennessee, 38120

  • Pfizer Investigational Site

    Memphis, Tennessee, 38138

  • Pfizer Investigational Site

    Meridian, Idaho, 83642

  • Pfizer Investigational Site

    Milwaukee, Wisconsin, 53209

  • Pfizer Investigational Site

    Milwaukee, Wisconsin, 53226

  • Pfizer Investigational Site

    Minot, North Dakota, 58701

  • Pfizer Investigational Site

    Minot, North Dakota, 58702

  • Pfizer Investigational Site

    Missoula, Montana, 59801

  • Pfizer Investigational Site

    Missoula, Montana, 59802

  • Pfizer Investigational Site

    Missoula, Montana, 59804

  • Pfizer Investigational Site

    Mobile, Alabama, 36608

  • Pfizer Investigational Site

    Mt. Pleasant, South Carolina, 29464

  • Pfizer Investigational Site

    Nashville, Tennessee, 37203

  • Pfizer Investigational Site

    New Hyde Park, New York, 11042

  • Pfizer Investigational Site

    New York, New York, 10029

  • Pfizer Investigational Site

    Newark, Delaware, 19713

  • Pfizer Investigational Site

    Newtown, Pennsylvania, 18940

  • Pfizer Investigational Site

    Norfolk, Virginia, 23502

  • Pfizer Investigational Site

    North Las Vegas, Nevada, 89030

  • Pfizer Investigational Site

    Oakes, North Dakota, 58574

  • Pfizer Investigational Site

    Oakland, California, 94612

  • Pfizer Investigational Site

    Ocean City, New Jersey, 07712

  • Pfizer Investigational Site

    Oklahoma City, Oklahoma, 73102

  • Pfizer Investigational Site

    Oklahoma City, Oklahoma, 73112-4481

  • Pfizer Investigational Site

    Oklahoma City, Oklahoma, 73120

  • Pfizer Investigational Site

    Oklahoma City, Oklahoma, 73142

  • Pfizer Investigational Site

    Ormond Beach, Florida, 32174

  • Pfizer Investigational Site

    Palm Beach Gardens, Florida, 33410

  • Pfizer Investigational Site

    Palm Desert, California, 92260

  • Pfizer Investigational Site

    Palm Harbor, Florida, 34684

  • Pfizer Investigational Site

    Palm Springs, California, 92260

  • Pfizer Investigational Site

    Palm Springs, California, 92262

  • Pfizer Investigational Site

    Palm Springs, California, 92263

  • Pfizer Investigational Site

    Pembroke Pines, Florida, 33027

  • Pfizer Investigational Site

    Pembroke Pines, Florida, 33029

  • Pfizer Investigational Site

    Peoria, Illinois, 61614

  • Pfizer Investigational Site

    Phoenix, Arizona, 85007

  • Pfizer Investigational Site

    Phoenix, Arizona, 85013-3903

  • Pfizer Investigational Site

    Phoenix, Arizona, 85013

  • Pfizer Investigational Site

    Phoenix, Arizona, 85015

  • Pfizer Investigational Site

    Phoenix, Arizona, 85016

  • Pfizer Investigational Site

    Phoenix, Arizona, 85020

  • Pfizer Investigational Site

    Phoenix, Arizona, 85027

  • Pfizer Investigational Site

    Phoenix, Arizona, 85050

  • Pfizer Investigational Site

    Plantation, Florida, 33324

  • Pfizer Investigational Site

    Port Orange, Florida, 32127

  • Pfizer Investigational Site

    Princeton, New Jersey, 08542

  • Pfizer Investigational Site

    Rancho Mirage, California, 92270

  • Pfizer Investigational Site

    Reno, Nevada, 89502-1196

  • Pfizer Investigational Site

    Reno, Nevada, 89503

  • Pfizer Investigational Site

    Riverdale, Georgia, 30274

  • Pfizer Investigational Site

    Robbinsdale, Minnesota, 55422

  • Pfizer Investigational Site

    Sacramento, California, 95816

  • Pfizer Investigational Site

    Sacramento, California, 95817

  • Pfizer Investigational Site

    Sacramento, California, 95825

  • Pfizer Investigational Site

    Salt Lake City, Utah, 84102-3015

  • Pfizer Investigational Site

    San Antonio, Texas, 78220

  • Pfizer Investigational Site

    San Antonio, Texas, 78229-3894

  • Pfizer Investigational Site

    San Antonio, Texas, 78229

  • Pfizer Investigational Site

    San Diego, California, 92108

  • Pfizer Investigational Site

    San Diego, California, 92120

  • Pfizer Investigational Site

    Sarasota, Florida, 34231

  • Pfizer Investigational Site

    Sarasota, Florida, 34239

  • Pfizer Investigational Site

    Scottsdale, Arizona, 85251

  • Pfizer Investigational Site

    Scottsdale, Arizona, 85254

  • Pfizer Investigational Site

    Seattle, Washington, 98105-4631

  • Pfizer Investigational Site

    Seattle, Washington, 98105

  • Pfizer Investigational Site

    Seattle, Washington, 98133

  • Pfizer Investigational Site

    Seattle, Washington, 98195

  • Pfizer Investigational Site

    Sellersville, Pennsylvania, 18960

  • Pfizer Investigational Site

    Shoreview, Minnesota, 55126

  • Pfizer Investigational Site

    Silver Spring, Maryland, 20902

  • Pfizer Investigational Site

    Sioux Falls, South Dakota, 57105

  • Pfizer Investigational Site

    Spokane, Washington, 99204

  • Pfizer Investigational Site

    St Louis, Missouri, 63141

  • Pfizer Investigational Site

    St. Petersburg, Florida, 33710

  • Pfizer Investigational Site

    Temple, Texas, 76504

  • Pfizer Investigational Site

    The Bronx, New York, 10461

  • Pfizer Investigational Site

    Tulsa, Oklahoma, 74135

  • Pfizer Investigational Site

    Upland, California, 91786

  • Pfizer Investigational Site

    Virginia Beach, Virginia, 23454

  • Pfizer Investigational Site

    Waco, Texas, 76708

  • Pfizer Investigational Site

    Washington D.C., District of Columbia, 20006

  • Pfizer Investigational Site

    Washington D.C., District of Columbia, 20007-2197

  • Pfizer Investigational Site

    Washington D.C., District of Columbia, 20007

  • Pfizer Investigational Site

    Washington D.C., District of Columbia, 20037

  • Pfizer Investigational Site

    Waterbury, Connecticut, 06708

  • Pfizer Investigational Site

    Waterdown, South Dakota, 57201

  • Pfizer Investigational Site

    Watertown, South Dakota, 57201

  • Pfizer Investigational Site

    West Palm Beach, Florida, 33401

  • Pfizer Investigational Site

    West Palm Beach, Florida, 33407

  • Pfizer Investigational Site

    West Palm Beach, Florida, 33409

  • Pfizer Investigational Site

    West Palm Beach, Florida, 33417

  • Pfizer Investigational Site

    West Reading, Pennsylvania, 19611

  • Pfizer Investigational Site

    Wheat Ridge, Colorado, 80033

  • Pfizer Investigational Site

    Wheaton, Maryland, 20902

  • Pfizer Investigational Site

    Whittier, California, 90602

  • Pfizer Investigational Site

    Winston-Salem, North Carolina, 27103

  • Pfizer Investigational Site

    Wyomissing, Pennsylvania, 19610

  • Pfizer Investigational Site

    Yukon, Oklahoma, 73099

Other trials in United States

Canada22 sites
  • Pfizer Investigational Site

    Calgary, Alberta, T2N 4Z6

  • Pfizer Investigational Site

    Gatineau, Quebec, J8Y 6S9

  • Pfizer Investigational Site

    Hamilton, Ontario, L8N 1Y2

  • Pfizer Investigational Site

    Hawkesbury, Ontario, K6A 1A1

  • Pfizer Investigational Site

    Hawkesbury, Ontario, K6A 3B2

  • Pfizer Investigational Site

    London, Ontario, N6A 4V2

  • Pfizer Investigational Site

    Montreal, Quebec, H2L 1S6

  • Pfizer Investigational Site

    Montreal, Quebec, H2X 1N8

  • Pfizer Investigational Site

    Pointe-Claire, Quebec, H9R 4S3

  • Pfizer Investigational Site

    Québec, Quebec, G1S 2L6

  • Pfizer Investigational Site

    Québec, Quebec, G1V 3M7

  • Pfizer Investigational Site

    Saskatoon, Saskatchewan, S7K 0H6

  • Pfizer Investigational Site

    Saskatoon, Saskatchewan, S7K 1N4

  • Pfizer Investigational Site

    Sherbrooke, Quebec, J1H 4J6

  • Pfizer Investigational Site

    Toronto, Ontario, M5C 1R6

  • Pfizer Investigational Site

    Toronto, Ontario, M5C 2T2

  • Pfizer Investigational Site

    Toronto, Ontario, M5G 1E2

  • Pfizer Investigational Site

    Toronto, Ontario, MB5 1W8

  • Pfizer Investigational Site

    Trois-Rivières, Quebec, G8Z 1Y2

  • Pfizer Investigational Site

    Vancouver, British Columbia, V5Z 2N6

  • Pfizer Investigational Site

    Vancouver, British Columbia, V6H 3X8

  • Pfizer Investigational Site

    Winnipeg, Manitoba, R3A 1M3

Other trials in Canada

Poland17 sites
  • Pfizer Investigational Site

    Katowice, Poland, 40-084

  • Pfizer Investigational Site

    Krakow, Krakow, 30-510

  • Pfizer Investigational Site

    Krakow, 30-007

  • Pfizer Investigational Site

    Krakow, 30-017

  • Pfizer Investigational Site

    Krakow, 30-224

  • Pfizer Investigational Site

    Krakow, 31-501

  • Pfizer Investigational Site

    Lublin, 20-090

  • Pfizer Investigational Site

    Warsaw, Poland, 03-335

  • Pfizer Investigational Site

    Warsaw, 00-315

  • Pfizer Investigational Site

    Warsaw, 00-418

  • Pfizer Investigational Site

    Warsaw, 00-655

  • Pfizer Investigational Site

    Warsaw, 00-699

  • Pfizer Investigational Site

    Warsaw, 00-909

  • Pfizer Investigational Site

    Warsaw, 02-341

  • Pfizer Investigational Site

    Warsaw, 02-796

  • Pfizer Investigational Site

    Warsaw, 04-730

  • Pfizer Investigational Site

    Wroclaw, Poland, 50-088

Other trials in Poland

South Africa13 sites
  • Pfizer Investigational Site

    Bedford Gardens

  • Pfizer Investigational Site

    Groenkloof, Pretoria

  • Pfizer Investigational Site

    Johannesburg, South Africa, 2193

  • Pfizer Investigational Site

    Johannesburg, 2193

  • Pfizer Investigational Site

    Johannesburg, 2196

  • Pfizer Investigational Site

    Johannesburg

  • Pfizer Investigational Site

    Parow, 7500

  • Pfizer Investigational Site

    Parow

  • Pfizer Investigational Site

    Pretoria, South Africa, 0181

  • Pfizer Investigational Site

    Pretoria, 0042

  • Pfizer Investigational Site

    Pretoria

  • Pfizer Investigational Site

    Somerset West

  • Pfizer Investigational Site

    Stellenbosch

Other trials in South Africa

Russia12 sites
  • Pfizer Investigational Site

    Moscow, 101990

  • Pfizer Investigational Site

    Moscow, 107014

  • Pfizer Investigational Site

    Moscow, 115522

  • Pfizer Investigational Site

    Moscow, 117036

  • Pfizer Investigational Site

    Moscow, 119002

  • Pfizer Investigational Site

    Moscow, 121356

  • Pfizer Investigational Site

    Moscow, 127299

  • Pfizer Investigational Site

    Moscow, 129010

  • Pfizer Investigational Site

    Saint Petersburg, 1190068

  • Pfizer Investigational Site

    Saint Petersburg, 190068

  • Pfizer Investigational Site

    Saint Petersburg, 194291

  • Pfizer Investigational Site

    Saint Petersburg, 199034

Other trials in Russia

Bulgaria11 sites
  • Pfizer Investigational Site

    Pleven, 5800

  • Pfizer Investigational Site

    Plovdiv, Bulgaria, 4002

  • Pfizer Investigational Site

    Plovdiv, 4002

  • Pfizer Investigational Site

    Sofia, Bulgaria, 1301

  • Pfizer Investigational Site

    Sofia, Bulgaria, 1431

  • Pfizer Investigational Site

    Sofia, Bulgaria, 1504

  • Pfizer Investigational Site

    Sofia, 1301

  • Pfizer Investigational Site

    Sofia, 1303

  • Pfizer Investigational Site

    Sofia, 1407

  • Pfizer Investigational Site

    Sofia, 1431

  • Pfizer Investigational Site

    Sofia, 1504

Other trials in Bulgaria

Finland9 sites
  • Pfizer Investigational Site

    Jyväskylä, FIN, 40100

  • Pfizer Investigational Site

    Jyväskylä, 40700

  • Pfizer Investigational Site

    Jyväskylä, FIN-40100

  • Pfizer Investigational Site

    Kuopio, 70210

  • Pfizer Investigational Site

    Kuopio, 70211

  • Pfizer Investigational Site

    Kuopio, FIN-70211

  • Pfizer Investigational Site

    Lahti

  • Pfizer Investigational Site

    Oulu, Finland, 90 100

  • Pfizer Investigational Site

    Turku, 20100

Other trials in Finland

Romania7 sites
  • Pfizer Investigational Site

    Bucharest, 050521

  • Pfizer Investigational Site

    Bucharest, 7000

  • Pfizer Investigational Site

    Bucharest, 70231

  • Pfizer Investigational Site

    Bucharesti, 7000

  • Pfizer Investigational Site

    Cluj-Napoca, Napoca, 400000

  • Pfizer Investigational Site

    Cluj-Napoca, 400349

  • Pfizer Investigational Site

    Iași, Iaşi, 700111

Other trials in Romania

Belgium6 sites
  • Pfizer Investigational Site

    Diepenbeek, 3590

  • Pfizer Investigational Site

    Genk, 3600

  • Pfizer Investigational Site

    Ghent, Belgium, 9000

  • Pfizer Investigational Site

    Leuven, 3000

  • Pfizer Investigational Site

    Liège, Liege, 4000

  • Pfizer Investigational Site

    Schiepsebos, 6

Other trials in Belgium

Brazil6 sites
  • Pfizer Investigational Site

    Duque de Caxias - Cuiaba, Mato Grosso, 78043-306

  • Pfizer Investigational Site

    Goiânia, Goiás, 74175-080

  • Pfizer Investigational Site

    Rio de Janeiro, Rio de Janeiro, 20020-020

  • Pfizer Investigational Site

    Rio de Janeiro, Rio de Janeiro, 22271-100

  • Pfizer Investigational Site

    SĂŁo Paulo, SĂŁo Paulo, 04020-060

  • Pfizer Investigational Site

    Sorocaba, SĂŁo Paulo, 18095-450

Other trials in Brazil

Netherlands6 sites
  • Pfizer Investigational Site

    Amsterdam, HV, 1081

  • Pfizer Investigational Site

    Eindhoven, 5611 NJ

  • Pfizer Investigational Site

    Emmen, Drenthe, 7824 AA

  • Pfizer Investigational Site

    Nijmegen, GA, 6525

  • Pfizer Investigational Site

    Nijmegen, SZ, 6532

  • Pfizer Investigational Site

    Rotterdam, 3001 HG

Other trials in Netherlands

Norway6 sites
  • Pfizer Investigational Site

    Bergen, NO-5094

  • Pfizer Investigational Site

    Hamar, 2317

  • Pfizer Investigational Site

    Oslo, NO-0164

  • Pfizer Investigational Site

    Oslo, NO-0176

  • Pfizer Investigational Site

    Trondheim, 7006

  • Pfizer Investigational Site

    Trondheim, NO-7006

Other trials in Norway

Australia5 sites
  • Pfizer Investigational Site

    Concord, New South Wales, 2139

  • Pfizer Investigational Site

    Herston, QLD 4029

  • Pfizer Investigational Site

    Keswick

  • Pfizer Investigational Site

    Nedlands, Western Australia, 6009

  • Pfizer Investigational Site

    St Leonards, New South Wales, 2065

Other trials in Australia

Slovakia5 sites
  • Pfizer Investigational Site

    Bratislava, 826 06

  • Pfizer Investigational Site

    Bratislava, 833 01

  • Pfizer Investigational Site

    Bratislava, 83301

  • Pfizer Investigational Site

    Bratislava, 851 07

  • Pfizer Investigational Site

    Piešťany, Slovak Republic

Other trials in Slovakia

Spain5 sites
  • Pfizer Investigational Site

    Madrid, Madrid, 28046

  • Pfizer Investigational Site

    Madrid, Spain, 28009

  • Pfizer Investigational Site

    Madrid, 28006

  • Pfizer Investigational Site

    Madrid, 28009

  • Pfizer Investigational Site

    Madrid, 28040

Other trials in Spain

Estonia4 sites
  • Pfizer Investigational Site

    Tallinn, 10128

  • Pfizer Investigational Site

    Tartu, 50410

  • Pfizer Investigational Site

    Tartu, 51010

  • Pfizer Investigational Site

    Tartu

Other trials in Estonia

Hungary4 sites
  • Pfizer Investigational Site

    Békéscsaba, 5600

  • Pfizer Investigational Site

    H-6720 Szeged

  • Pfizer Investigational Site

    Kecskemét, 6000

  • Pfizer Investigational Site

    MakĂł, 6900

Other trials in Hungary

Italy4 sites
  • Pfizer Investigational Site

    Roma, 00136

  • Pfizer Investigational Site

    Roma, 00168

  • Pfizer Investigational Site

    Roma, 00189

  • Pfizer Investigational Site

    Siena, 53100

Other trials in Italy

New Zealand4 sites
  • Pfizer Investigational Site

    Auckland

  • Pfizer Investigational Site

    Christchurch, NZ, 8143

  • Pfizer Investigational Site

    Dunedin

  • Pfizer Investigational Site

    Milford, Auckland

Other trials in New Zealand

Denmark3 sites
  • Pfizer Investigational Site

    Aalborg, 9000

  • Pfizer Investigational Site

    Ballerup Municipality, 2750

  • Pfizer Investigational Site

    Vejle, 7100

Other trials in Denmark

France3 sites
  • Pfizer Investigational Site

    Lyon, 69437

  • Pfizer Investigational Site

    Orléans, 45032

  • Pfizer Investigational Site

    Paris, 75015

Other trials in France

Germany3 sites
  • Pfizer Investigational Site

    Berlin, 12200

  • Pfizer Investigational Site

    MĂĽnchen, 80809

  • Pfizer Investigational Site

    Zerbst, 39261

Other trials in Germany

Hong Kong3 sites
  • Pfizer Investigational Site

    Hong Kong

  • Pfizer Investigational Site

    PRC

  • Pfizer Investigational Site

    Sai Ying Pung

Other trials in Hong Kong

Lithuania3 sites
  • Pfizer Investigational Site

    Kaunas, LT-50009

  • Pfizer Investigational Site

    Vilnius, LT-04130

  • Pfizer Investigational Site

    Vilnius, LT-10318

Other trials in Lithuania

Mexico3 sites
  • Pfizer Investigational Site

    Mexico City, 03100

  • Pfizer Investigational Site

    Mexico City, 11800

  • Pfizer Investigational Site

    Seccion de Lomas Verdes, State of Mexico, CP 53120

Other trials in Mexico

Croatia2 sites
  • Pfizer Investigational Site

    Zadar, 23000

  • Pfizer Investigational Site

    Zagreb, 10000

Other trials in Croatia

Argentina1 site
  • Pfizer Investigational Site

    Provincia de Buenos Aires

Other trials in Argentina

Austria1 site
  • Pfizer Investigational Site

    Graz, 8036

Other trials in Austria

Chile1 site
  • Pfizer Investigational Site

    Santiago

Other trials in Chile

Greece1 site
  • Pfizer Investigational Site

    Athens, Greece, 11526

Other trials in Greece

About this study

Official title: Fracture Incidence Reduction And Safety Of TSE-424 (Bazedoxifene Acetate) Compared To Placebo And Raloxifene In Osteoporotic Postmenopausal Women

The purpose of this study is to determine whether bazedoxifene acetate is safe and effective in the treatment of osteoporosis in postmenopausal women.

Conditions
Osteoporosis
Being tested
Bazedoxifene Acetate, Placebo
Keywords
Osteoporosis, Postmenopause
Medical subject headings
Osteoporosis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Bazedoxifene AcetateDrug

    BZA 20mg, daily, oral

  • PlaceboOther

    Placebo, daily, oral

Study groups in NCT00205777
Study groupRoleWhat they receive
AActive comparatorNot described
Receives: Drug: Bazedoxifene Acetate
BPlacebo comparatorNot described
Receives: Other: Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Percentage of Participants With New Vertebral Fractures Through Month 36

    New vertebral fracture: decrease in anterior, mid, or posterior vertebral (vt) height of approximately 20% and 4 millimeter (mm) or more from baseline (base) to end of study confirmed by measurement of involved vt body, a semi-quantitative grade change of 1 from base for any vertebra from fourth thoracic to fourth lumbar vertebra (T4 to L4), provided vertebra was not fractured at base. Participant was counted only once irrespective of how many new vt fractures were diagnosed. Stratification factor was base fracture status, categorized as no prevalent fracture and at least 1 prevalent fracture.

    Measured: Baseline through Month 36

  2. Percentage of Participants With New Vertebral Fractures Through Month 60

    New vertebral fracture: decrease in anterior, mid, or posterior vt height of approximately 20% and 4 millimeter (mm) or more from baseline (base) to end of study confirmed by measurement of involved vt body, a semi-quantitative grade change of 1 from base for any vertebra from fourth thoracic to fourth lumbar vertebra (T4 to L4), provided vertebra was not fractured at base. Participant was counted only once irrespective of how many new vt fractures were diagnosed. Stratification factor was base fracture status, categorized as no prevalent fracture and at least 1 prevalent fracture.

    Measured: Baseline through Month 60

  3. Percentage of Participants With New Vertebral Fractures Through Month 84

    New vertebral fracture: decrease in anterior, mid, or posterior vt height of approximately 20% and 4 millimeter (mm) or more from baseline (base) to end of study confirmed by measurement of involved vt body, a semi-quantitative grade change of 1 from base for any vertebra from fourth thoracic to fourth lumbar vertebra (T4 to L4), provided vertebra was not fractured at base. Participant was counted only once irrespective of how many new vt fractures were diagnosed. Stratification factor was base fracture status, categorized as no prevalent fracture and at least 1 prevalent fracture.

    Measured: Baseline through Month 84

Secondary outcomes (57)
  1. Incidence of Breast Cancer Through Month 36

    Incidence of breast cancer was defined as the number of participants with breast cancer diagnosis by the time point of interest divided by the number of participants included in the analysis. The reported rate was rescaled to reflect average follow-up time per 1000 women (1000 multiplied by number of cases divided by total follow-up time).

    Measured: Baseline through Month 36

  2. Incidence of Breast Cancer Through Month 60

    Incidence of breast cancer was defined as the number of participants with breast cancer diagnosis by the time point of interest divided by the number of participants included in the analysis. The reported rate was rescaled to reflect average follow-up time per 1000 women (1000 multiplied by number of cases divided by total follow-up time).

    Measured: Baseline through Month 60

  3. Incidence of Breast Cancer Through Month 84

    Incidence of breast cancer was defined as the number of participants with breast cancer diagnosis by the time point of interest divided by the number of participants included in the analysis. The reported rate was rescaled to reflect average follow-up time per 1000 women (1000 multiplied by number of cases divided by total follow-up time).

    Measured: Baseline through Month 84

  4. Percentage of Participants With New Clinical Vertebral Fractures Through Month 36

    A new clinical vertebral fracture was defined as a new fracture found at any time because of back pain suggestive of fracture(s). New Clinical vertebral fractures were verified with radiographic assessment using both semi-quantitative and quantitative morphometric assessment: decrease in anterior, mid, or posterior vt height of approximately 20% and 4 mm or more from base to end of study confirmed by measurement of involved vt body, a semi-quantitative grade change of 1 from base for any vertebra from T4 to L4, provided vertebra was not fractured at base.

    Measured: Baseline through Month 36

  5. Percentage of Participants With New Clinical Vertebral Fractures Through Month 60

    A new clinical vertebral fracture was defined as a new fracture found at any time because of back pain suggestive of fracture(s). New Clinical vertebral fractures were verified with radiographic assessment using both semi-quantitative and quantitative morphometric assessment: decrease in anterior, mid, or posterior vt height of approximately 20% and 4 mm or more from base to end of study confirmed by measurement of involved vt body, a semi-quantitative grade change of 1 from base for any vertebra from T4 to L4, provided vertebra was not fractured at base.

    Measured: Baseline through Month 60

  6. Percentage of Participants With New Clinical Vertebral Fractures Through Month 84

    A new clinical vertebral fracture was defined as a new fracture found at any time because of back pain suggestive of fracture(s). New Clinical vertebral fractures were verified with radiographic assessment using both semi-quantitative and quantitative morphometric assessment: decrease in anterior, mid, or posterior vt height of approximately 20% and 4 mm or more from base to end of study confirmed by measurement of involved vt body, a semi-quantitative grade change of 1 from base for any vertebra from T4 to L4, provided vertebra was not fractured at base.

    Measured: Baseline through Month 84

  7. Number of Participants With Worsening Vertebral Fractures Through Month 36

    A worsening vertebral fracture was defined as a decrease in anterior, mid, or posterior vertebral height of at least 20% and at least 4 mm as evaluated by quantitative morphometric assessment, and a grade change of at least 1 as rated by a radiologist using the semi-quantitative rating scale. It can occur only in a vertebra that was fractured at baseline.

    Measured: Baseline through Month 36

  8. Number of Participants With Worsening Vertebral Fractures Through Month 60

    A worsening vertebral fracture was defined as a decrease in anterior, mid, or posterior vertebral height of at least 20% and at least 4 mm as evaluated by quantitative morphometric assessment, and a grade change of at least 1 as rated by a radiologist using the semi-quantitative rating scale. It can occur only in a vertebra that was fractured at baseline.

    Measured: Baseline through Month 60

  9. Number of Participants With Worsening Vertebral Fractures Through Month 84

    A worsening vertebral fracture was defined as a decrease in anterior, mid, or posterior vertebral height of at least 20% and at least 4 mm as evaluated by quantitative morphometric assessment, and a grade change of at least 1 as rated by a radiologist using the semi-quantitative rating scale. It can occur only in a vertebra that was fractured at baseline.

    Measured: Baseline through Month 84

  10. Percentage of Participants With Non-vertebral Fractures Through Month 36

    Non-vertebral fractures were determined by direct questioning at each clinic visit after medication therapy begins. Osteoporosis-related, hip and wrist fractures were summarized.

    Measured: Baseline through Month 36

  11. Percentage of Participants With Non-vertebral Fractures Through Month 60

    Non-vertebral fractures were determined by direct questioning at each clinic visit after medication therapy begins. Osteoporosis-related, hip and wrist fractures were summarized.

    Measured: Baseline through Month 60

  12. Percentage of Participants With Non-vertebral Fractures Through Month 84

    Non-vertebral fractures were determined by direct questioning at each clinic visit after medication therapy begins. Osteoporosis-related, hip and wrist fractures were summarized.

    Measured: Baseline through Month 84

  13. Change From Baseline in Height at Month 36

    Height was measured 3 times using standardized Harpenden stadiometer (height based on the middle stadiometer reading was recorded).

    Measured: Baseline, Month 36

  14. Change From Baseline in Height at Month 60

    Height was measured 3 times using standardized Harpenden stadiometer (height based on the middle stadiometer reading was recorded).

    Measured: Baseline, Month 60

  15. Change From Baseline in Height at Month 84

    Height (cm) was measured 3 times using standardized Harpenden stadiometer (height based on the middle stadiometer reading was recorded).

    Measured: Baseline, Month 84

  16. Percent Change From Baseline in Bone Mineral Density (BMD) at Month 6, 12, 18, 24 and 36

    BMD of lumbar spine (Lu Sp) and hip (total hip [Tl Hp], femoral neck [Fe Ne] and femur trochanter [Fe Tr]) was evaluated by dual-energy x-ray absorptiometry (DXA). The left hip was evaluated unless prevented by pathology, in which case the right hip was evaluated throughout the study. Results were scored as T score, defined as BMD at the site when compared to the young normal reference mean. Normal BMD is a T-score of -1.0 or higher.

    Measured: Baseline, Months 6, 12, 18, 24, 36

  17. Percent Change From Baseline in Bone Mineral Density (BMD) at Months 48, 60

    BMD of lumbar spine (Lu Sp) and hip (total hip [Tl Hp], femoral neck [Fe Ne] and femur trochanter [Fe Tr]) was evaluated by dual-energy x-ray absorptiometry (DXA). The left hip was evaluated unless prevented by pathology, in which case the right hip was evaluated throughout the study. Results were scored as T score, defined as BMD at the site when compared to the young normal reference mean. Normal BMD is a T-score of -1.0 or higher.

    Measured: Baseline, Month 48, 60

  18. Percent Change From Baseline in Bone Mineral Density (BMD) at Months 72 and 84

    BMD of lumbar spine (Lu Sp) and hip (total hip [Tl Hp], femoral neck [Fe Ne] and femur trochanter [Fe Tr]) was evaluated by dual-energy x-ray absorptiometry (DXA). The left hip was evaluated unless prevented by pathology, in which case the right hip was evaluated throughout the study. Results were scored as T score, defined as BMD at the site when compared to the young normal reference mean. Normal BMD is a T-score of -1.0 or higher.

    Measured: Baseline, Month 72, 84

  19. Percent Change From Baseline in Osteocalcin at Month 3, 6 and 12

    Osteocalcin is a biochemical marker of bone formation. Blood samples were collected to evaluate osteocalcin levels.

    Measured: Baseline, Months 3, 6, 12

  20. Percent Change From Baseline in Osteocalcin at Months 36 and 60

    Osteocalcin is a biochemical marker of bone formation. Blood samples were collected to evaluate osteocalcin levels.

    Measured: Baseline, Months 36, 60

  21. Percent Change From Baseline in Osteocalcin at Months 72 and 84

    Osteocalcin is a biochemical marker of bone formation. Blood samples were collected to evaluate osteocalcin levels.

    Measured: Baseline, Months 72, 84

  22. Percent Change From Baseline in C-telopeptide (CTx) at Month 3, 6 and 12

    C-telopeptide is a biochemical marker of bone formation. Blood samples were collected to evaluate C-telopeptide levels.

    Measured: Baseline, Months 3, 6, 12

  23. Percent Change From Baseline in C-telopeptide (CTx) at Months 36 and 60

    C-telopeptide is a biochemical marker of bone formation. Blood samples were collected to evaluate C-telopeptide levels.

    Measured: Baseline, Months 36, 60

  24. Percent Change From Baseline in C-telopeptide (CTx) at Months 72 and 84

    C-telopeptide is a biochemical marker of bone formation. Blood samples were collected to evaluate C-telopeptide levels.

    Measured: Baseline, Months 72, 84

  25. Percent Change From Baseline in Lipid Parameters at Months 6, 12, 24 and 36

    Lipid parameters evaluated included total cholesterol (TC), low density lipoprotein (LDL), high density lipoprotein (HDL), triglyceride (TG), high-density lipoprotein fraction 2 (HDL2) and high-density lipoprotein fraction 3 (HDL3).

    Measured: Baseline, Months 6, 12, 24, 36

  26. Bone Histomorphometric Indices at Month 36: BV, OV, OS, OcS, ObS, MS, ES, OMS, CP

    Bone histomorphometry verified rate of bone remodeling. Anterior iliac crest bone biopsy done to exclude presence of osteomalacia or more subtle defects in mineralization; investigated qualitative aspects of bone. Also assessed decrease in rate of bone turnover, investigated mechanism for observed increase in BMD. Percentage of following indices (volume,surface,porosity) was calculated:Bone Volume(BV), Osteoid Volume(OV), Osteoid Surface(OS), Osteoclast Surface(OcS), Osteoblast Surface(ObS), Mineralizing surface(MS), Eroded Surface(ES), Osteoid Mineralizing surface(OMS), Cortical porosity(CP).

    Measured: Month 36

  27. Bone Histomorphometric Indices at Month 60: BV, OV, OS, OcS, ObS, MS, ES, OMS, CP

    Bone histomorphometry verified rate of bone remodeling. Anterior iliac crest bone biopsy done to exclude presence of osteomalacia or more subtle defects in mineralization; investigated qualitative aspects of bone. Also assessed decrease in rate of bone turnover, investigated mechanism for observed increase in BMD. Percentage of following indices (volume,surface,porosity) was calculated:Bone Volume(BV), Osteoid Volume(OV), Osteoid Surface(OS), Osteoclast Surface(OcS), Osteoblast Surface(ObS), Mineralizing surface(MS), Eroded Surface(ES), Osteoid Mineralizing surface(OMS), Cortical porosity(CP).

    Measured: Month 60

  28. Bone Histomorphometric Indices at Month 36: WTh, OTh, TbTh, TbSp and CTh

    Bone histomorphometry verified rate of bone remodeling. Anterior iliac crest bone biopsy done to exclude presence of osteomalacia or more subtle defects in mineralization; investigated qualitative aspects of bone. Also assessed decrease in rate of bone turnover, investigated mechanism for observed increase in BMD. Calculated indices included: Wall Thickness (WTh), Osteoid Thickness (OTh), Trabecular Thickness (TbTh), Trabecular Separation (TbSp) and Cortical thickness (CTh). Trabecular separation defined as the thickness of the spaces as defined by binarization within the volume of interest.

    Measured: Month 36

  29. Bone Histomorphometric Indices at Month 60: WTh, OTh, TbTh, TbSp and CTh

    Bone histomorphometry verified rate of bone remodeling. Anterior iliac crest bone biopsy done to exclude presence of osteomalacia or more subtle defects in mineralization; investigated qualitative aspects of bone. Also assessed decrease in rate of bone turnover, investigated mechanism for observed increase in BMD. Calculated indices included: WTh, OTh, TbTh, TbSp and CTh. Trabecular separation defined as the thickness of the spaces as defined by binarization within the volume of interest.

    Measured: Month 60

  30. Bone Histomorphometric Indices at Month 36: Total Surface (Goldner Slide) [TSG]

    Bone histomorphometry verified rate of bone remodeling. Anterior iliac crest bone biopsy done to exclude presence of osteomalacia or more subtle defects in mineralization; investigated qualitative aspects of bone. Also assessed decrease in rate of bone turnover, investigated mechanism for observed increase in BMD. Calculated indices included: Total Surface (Goldner Slide) [TSG]. All specimens were demineralized and subjected to staining procedures (Goldner's staining). Slides were analyzed using light microscopy for total surface area, the surface area that consisted of bone and the surface area that consisted of graft material (all in mm^2 and expressed as percent (%) of the total surface.

    Measured: Month 36

  31. Bone Histomorphometric Indices at Month 60: TSG

    Bone histomorphometry verified rate of bone remodeling. Anterior iliac crest bone biopsy done to exclude presence of osteomalacia or more subtle defects in mineralization; investigated qualitative aspects of bone. Also assessed decrease in rate of bone turnover, investigated mechanism for observed increase in BMD. Calculated indices included: Total Surface (Goldner Slide) [TSG]. All specimens were demineralized and subjected to staining procedures (Goldner's staining). Slides were analyzed using light microscopy for total surface area, the surface area that consisted of bone and the surface area that consisted of graft material (all in mm^2 and expressed as percent (%) of the total surface.

    Measured: Month 60

  32. Bone Histomorphometric Indices at Month 36: TtAr

    Bone histomorphometry verified rate of bone remodeling. Anterior iliac crest bone biopsy done to exclude presence of osteomalacia or more subtle defects in mineralization; investigated qualitative aspects of bone. Also assessed decrease in rate of bone turnover, investigated mechanism for observed increase in BMD. Calculated variable: Tissue Area (TtAr). Tissue area comprised of the porous calcified substance from which bones were made.

    Measured: Month 36

  33. Bone Histomorphometric Indices at Month 60: TtAr

    Bone histomorphometry verified rate of bone remodeling. Anterior iliac crest bone biopsy done to exclude presence of osteomalacia or more subtle defects in mineralization; investigated qualitative aspects of bone. Also assessed decrease in rate of bone turnover, investigated mechanism for observed increase in BMD. Calculated variable: Tissue Area (TtAr). Tissue area comprised of the porous calcified substance from which bones were made.

    Measured: Month 60

  34. Bone Histomorphometric Indices at Month 36: BFP, RP and RmP

    Bone histomorphometry verified rate of bone remodeling. Anterior iliac crest bone biopsy done to exclude presence of osteomalacia or more subtle defects in mineralization; investigated qualitative aspects of bone. Also assessed decrease in rate of bone turnover, investigated mechanism for observed increase in BMD. Calculated indices included: Bone Formation Period (BFP), Resorption Period (RP), Remodeling Period (RmP).

    Measured: Month 36

  35. Bone Histomorphometric Indices at Month 60: BFP, RP and RmP

    Bone histomorphometry verified rate of bone remodeling. Anterior iliac crest bone biopsy done to exclude presence of osteomalacia or more subtle defects in mineralization; investigated qualitative aspects of bone. Also assessed decrease in rate of bone turnover, investigated mechanism for observed increase in BMD. Calculated indices included: Bone Formation Period (BFP), Resorption Period (RP), Remodeling Period (RmP).

    Measured: Month 60

  36. Bone Histomorphometric Indices at Month 36: SuD

    Bone histomorphometry verified rate of bone remodeling. Anterior iliac crest bone biopsy done to exclude presence of osteomalacia or more subtle defects in mineralization; investigated qualitative aspects of bone. Also assessed decrease in rate of bone turnover, investigated mechanism for observed increase in BMD Calculated indices included: Surface Density (SuD).

    Measured: Month 36

  37. Bone Histomorphometric Indices at Month 60: SuD

    Bone histomorphometry verified rate of bone remodeling. Anterior iliac crest bone biopsy done to exclude presence of osteomalacia or more subtle defects in mineralization; investigated qualitative aspects of bone. Also assessed decrease in rate of bone turnover, investigated mechanism for observed increase in BMD Calculated indices included: Surface Density (SuD).

    Measured: Month 60

  38. Bone Histomorphometric Indices at Month 36: BFRTS

    Bone histomorphometry verified rate of bone remodeling. Anterior iliac crest bone biopsy done to exclude presence of osteomalacia or more subtle defects in mineralization; investigated qualitative aspects of bone. Also assessed decrease in rate of bone turnover, investigated mechanism for observed increase in BMD Calculated indices included: Bone Form Rate (BFR)-Total Surface Reference (BFRTS). BFR accounts the bone surface which is actively mineralizing, which depends on the number of osteoblasts that are active. BFR= Fraction of mineralizing surface and bone surface multiplied by mineralization apposition rate (MAR).

    Measured: Month 36

  39. Bone Histomorphometric Indices at Month 60: BFRTS

    Bone histomorphometry verified rate of bone remodeling. Anterior iliac crest bone biopsy done to exclude presence of osteomalacia or more subtle defects in mineralization; investigated qualitative aspects of bone. Also assessed decrease in rate of bone turnover, investigated mechanism for observed increase in BMD Calculated indices included: Bone Form Rate (BFR)-Total Surface Reference (BFRTS). BFR accounts the bone surface which is actively mineralizing, which depends on the number of osteoblasts that are active. BFR= Fraction of mineralizing surface and bone surface multiplied by mineralization apposition rate (MAR).

    Measured: Month 60

  40. Bone Histomorphometric Indices at Month 36: ACF

    Bone histomorphometry verified rate of bone remodeling. Anterior iliac crest bone biopsy done to exclude presence of osteomalacia or more subtle defects in mineralization; investigated qualitative aspects of bone. Also assessed decrease in rate of bone turnover, investigated mechanism for observed increase in BMD Calculated indices included: Activation Frequency (ACF). The total period (TP) is the duration between the beginning of one formation period (FP) and the beginning of the next FP. The number of times per year that this spot begins the FP is the activation frequency (ACF).

    Measured: Month 36

  41. Bone Histomorphometric Indices at Month 60: ACF

    Bone histomorphometry verified rate of bone remodeling. Anterior iliac crest bone biopsy done to exclude presence of osteomalacia or more subtle defects in mineralization; investigated qualitative aspects of bone. Also assessed decrease in rate of bone turnover, investigated mechanism for observed increase in BMD Calculated indices included: Activation Frequency (ACF). The total period (TP) is the duration between the beginning of one formation period (FP) and the beginning of the next FP. The number of times per year that this spot begins the FP is the activation frequency (ACF).

    Measured: Month 60

  42. Bone Histomorphometric Indices at Month 36: Mlt

    Bone histomorphometry verified rate of bone remodeling. Anterior iliac crest bone biopsy done to exclude presence of osteomalacia or more subtle defects in mineralization; investigated qualitative aspects of bone. Also assessed decrease in rate of bone turnover, investigated mechanism for observed increase in BMD Calculated indices included: Mineralization Lag Time (Mlt). Mineralization lag time was the lag between the time osteoid was formed and the mineral was added.

    Measured: Month 36

  43. Bone Histomorphometric Indices at Month 60: Mlt

    Bone histomorphometry verified rate of bone remodeling. Anterior iliac crest bone biopsy done to exclude presence of osteomalacia or more subtle defects in mineralization; investigated qualitative aspects of bone. Also assessed decrease in rate of bone turnover, investigated mechanism for observed increase in BMD Calculated indices included: Mineralization Lag Time (Mlt). Mineralization lag time was the lag between the time osteoid was formed and the mineral was added.

    Measured: Month 60

  44. Bone Histomorphometric Indices at Month 36: MAR

    Bone histomorphometry verified rate of bone remodeling. Anterior iliac crest bone biopsy done to exclude presence of osteomalacia or more subtle defects in mineralization; investigated qualitative aspects of bone. Also assessed decrease in rate of bone turnover, investigated mechanism for observed increase in BMD Calculated indices included: Mineral Apposition Rate (MAR). MAR is the area of new bone formed during the label interval.

    Measured: Month 36

  45. Bone Histomorphometric Indices at Month 60: MAR

    Bone histomorphometry verified rate of bone remodeling. Anterior iliac crest bone biopsy done to exclude presence of osteomalacia or more subtle defects in mineralization; investigated qualitative aspects of bone. Also assessed decrease in rate of bone turnover, investigated mechanism for observed increase in BMD Calculated indices included: Mineral Apposition Rate (MAR). MAR is the area of new bone formed during the label interval.

    Measured: Month 60

  46. Bone Histomorphometric Indices at Month 36: TbN

    Bone histomorphometry verified rate of bone remodeling. Anterior iliac crest bone biopsy done to exclude presence of osteomalacia or more subtle defects in mineralization; investigated qualitative aspects of bone. Also assessed decrease in rate of bone turnover, investigated mechanism for observed increase in BMD Calculated indices included: Trabecular Number (TbN). TbN= Ratio of bone volume to tissue volume divided by trabecular thickness.

    Measured: Month 36

  47. Bone Histomorphometric Indices at Month 60: TbN

    Bone histomorphometry verified rate of bone remodeling. Anterior iliac crest bone biopsy done to exclude presence of osteomalacia or more subtle defects in mineralization; investigated qualitative aspects of bone. Also assessed decrease in rate of bone turnover, investigated mechanism for observed increase in BMD Calculated indices included: Trabecular Number (TbN). TbN= Ratio of bone volume to tissue volume divided by trabecular thickness.

    Measured: Month 60

  48. Bone Histomorphometric Indices at Month 36: BFRBV

    Bone histomorphometry verified rate of bone remodeling. Anterior iliac crest bone biopsy done to exclude presence of osteomalacia or more subtle defects in mineralization; investigated qualitative aspects of bone. Also assessed decrease in rate of bone turnover, investigated mechanism for observed increase in BMD Calculated indices included: Bone Formation Rate (BFR)-Bone Volume Reference (BFRBV). BFR accounts the bone volume which is actively mineralizing, which depends on the number of osteoblasts that are active. BFR= Fraction of mineralizing volume and bone volume multiplied by mineralization apposition rate (MAR).

    Measured: Month 36

  49. Bone Histomorphometric Indices at Month 60: BFRBV

    Bone histomorphometry verified rate of bone remodeling. Anterior iliac crest bone biopsy done to exclude presence of osteomalacia or more subtle defects in mineralization; investigated qualitative aspects of bone. Also assessed decrease in rate of bone turnover, investigated mechanism for observed increase in BMD Calculated indices included: Bone Formation Rate (BFR)-Bone Volume Reference (BFRBV). BFR accounts the bone volume which is actively mineralizing, which depends on the number of osteoblasts that are active. BFR= Fraction of mineralizing volume and bone volume multiplied by mineralization apposition rate (MAR).

    Measured: Month 60

  50. Women's Health Questionnaire (WHQ)

    WHQ is a measure of mid-aged women's emotional and physical health. Consists of 36-item assessing nine domains of physical and emotional health: Depressed mood; Somatic symptoms; Anxiety/fears; Vasomotor symptoms; Sleep problems; Sexual behavior; Menstrual symptoms; Memory/concentration; and Attractiveness. Each item scored on a 4 point scale (yes definitely, yes sometimes, not much, no not at all) reduced to binary option as 0 (no) and 1 (yes). Domain subscale score was calculated as sum of domain items score divided by number of domain items. Total score was calculated as the sum of individual domain subscale score divided by number of domains. Total score range from 0 (absent) to 1 (present), with higher scores indicating more pronounced distress and dysfunction. Baseline values at different time points were considered only for the participants who were evaluable at those time points.

    Measured: Baseline

  51. Change From Baseline in Women's Health Questionnaire (WHQ) at Month 12, 24 and 36

    WHQ is a measure of mid-aged women's emotional and physical health. Consists of 36-item assessing nine domains of physical and emotional health: Depressed mood; Somatic symptoms; Anxiety/fears; Vasomotor symptoms; Sleep problems; Sexual behavior; Menstrual symptoms; Memory/concentration; and Attractiveness. Each item scored on a 4 point scale (yes definitely, yes sometimes, not much, no not at all) reduced to binary option as 0 (no) and 1 (yes). Domain subscale score was calculated as sum of domain items score divided by number of domain items. Total score was calculated as the sum of individual domain subscale score divided by number of domains. Total score range from 0 (absent) to 1 (present), with higher scores indicating more pronounced distress and dysfunction.Baseline values at different time points were considered only for the participants who were evaluable at those time points.

    Measured: Baseline, Months 12, 24, 36

  52. European Foundation for Osteoporosis Quality of Life Questionnaire (QUALEFFO)

    QUALEFFO is an osteoporosis-specific health instrument developed specifically for participants with vertebral deformities used to evaluate the effect of back pain and treatment on quality of life. The QUALEFFO questionnaire includes 41 items in 5 domains: pain, physical function, social function, general health perception, and mental function. The total score is calculated according to the scoring algorithm developed by the International Osteoporosis Foundation. Total scores are reported from 0 to 100, with lower scores corresponding to better quality of life. Baseline values at different time points were considered only for the participants who were evaluable at those time points.

    Measured: Baseline

  53. Change From Baseline in European Foundation for Osteoporosis Quality of Life Questionnaire (QUALEFFO) at Month 12, 24 and 36

    QUALEFFO is an osteoporosis-specific health instrument developed specifically for participants with vertebral deformities used to evaluate the effect of back pain and treatment on quality of life. The QUALEFFO questionnaire includes 41 items in 5 domains: pain, physical function, social function, general health perception, and mental function. The total score is calculated according to the scoring algorithm developed by the International Osteoporosis Foundation. Total scores are reported from 0 to 100, with lower scores corresponding to better quality of life. Baseline values at different time points were considered only for the participants who were evaluable at those time points.

    Measured: Baseline, Months 12, 24, 36

  54. Euro Quality of Life-5 Dimensions (EQ-5D) Visual Analog Scale (VAS)

    EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single index value. The VAS component rates current health state on a scale from 0 mm (worst imaginable health state) to 100 mm (best imaginable health state); higher scores indicate a better health state. Baseline values at different time points were considered only for the participants who were evaluable at those time points.

    Measured: Baseline

  55. Change From Baseline in Euro Quality of Life-5 Dimensions (EQ-5D) Visual Analog Scale (VAS) at Month 12, 24 and 36

    EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single index value. The VAS component rates current health state on a scale from 0 mm (worst imaginable health state) to 100 mm (best imaginable health state); higher scores indicate a better health state. Baseline values at different time points were considered only for the participants who were evaluable at those time points.

    Measured: Baseline, Months 12, 24, 36

  56. Euro Quality of Life-5 Dimensions (EQ-5D)- Health State Profile Utility Score

    EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed"). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state. Baseline values at different time points were considered only for the participants who were evaluable at those time points.

    Measured: Baseline

  57. Change From Baseline in Euro Quality of Life-5 Dimensions (EQ-5D)- Health State Profile Utility Score at Month 12, 24 and 36

    EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed"). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state. Baseline values at different time points were considered only for the participants who were evaluable at those time points.

    Measured: Baseline, Months 12, 24, 36

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted20 Sep 2005 (estimated)
  2. Study startDec 2001
  3. Primary completionSep 2010
  4. Study completionSep 2010

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Single group
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
7,609 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00205777
Sponsor's protocol ID
3068A1-301
Other IDs
B1781001
Status last verified
Feb 2013
First submitted
16 Sep 2005
Last updated
10 Apr 2013
Data monitoring committee
No

Publications

  • Christiansen C, Chesnut CH 3rd, Adachi JD, Brown JP, Fernandes CE, Kung AW, Palacios S, Levine AB, Chines AA, Constantine GD. Safety of bazedoxifene in a randomized, double-blind, placebo- and active-controlled Phase 3 study of postmenopausal women with osteoporosis. BMC Musculoskelet Disord. 2010 Jun 22;11:130. doi: 10.1186/1471-2474-11-130.

    PubMed 20569451

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing Bazedoxifene Acetate in people with Osteoporosis, run by Pfizer at 375 sites in 30 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 10 Apr 2013. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 375 sites in United States, Canada, Poland, South Africa, Russia and 25 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 10 Apr 2013). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Percentage of Participants With New Vertebral Fractures Through Month 36 (time frame: Baseline through Month 36). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT00205777, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Apr 2013.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in